![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Development of Potent Novel Oral Pan-genotypic HCV Nucleotide,
NS5A, NS5B Non-nucleoside, and Helicase Inhibitors
|
|
|
Reported by Jules Levin
HEP DART 2015, December 6-10, 2015, Wailea, Hawaii
Douglas L. Mayers, MD
AASLD: Preclinical characterization of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C- (11/23/15)
![HepDart1.gif](../images/121415/121415-6/HepDart1.gif)
![HepDart2.gif](../images/121415/121415-6/HepDart2.gif)
![HepDart3.gif](../images/121415/121415-6/HepDart3.gif)
![HepDart4.gif](../images/121415/121415-6/HepDart4.gif)
![HepDart5.gif](../images/121415/121415-6/HepDart5.gif)
![HepDart6.gif](../images/121415/121415-6/HepDart6.gif)
![HepDart7.gif](../images/121415/121415-6/HepDart7.gif)
![HepDart8.gif](../images/121415/121415-6/HepDart8.gif)
![HepDart9.gif](../images/121415/121415-6/HepDart9.gif)
![HepDart10.gif](../images/121415/121415-6/HepDart10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|